Comparison of baseline characteristics among celecoxib and traditional nonsteroidal antiinflammatory drug (tNSAID) users between the post- versus pre-period: logistic regression. Data are OR (95% CI).
| Post- vs Pre-period | ||
|---|---|---|
| Celecoxib | tNSAID | |
| No. patients | — | — |
| Age ≥ 65 yrs | 0.83 (0.81, 0.85) | 0.88 (0.86, 0.90) |
| Female | 0.95 (0.93, 0.96) | 1.14 (1.13, 1.16) |
| Higher income | 0.96 (0.95, 0.98) | 0.99 (0.98, 1.01) |
| Prescriber specialty | ||
| Rheumatologist | 1 (reference) | 1 (reference) |
| General practitioner | 0.95 (0.91, 0.99) | 1.07 (1.02, 1.12) |
| Internal medicine | 0.86 (0.79, 0.93) | 0.88 (0.81, 0.95) |
| Other | 0.91 (0.86, 0.95) | 1.02 (0.97, 1.07) |
| Renewal prescription | 0.81 (0.80, 0.83) | 0.71 (0.70, 0.72) |
| Rheumatoid arthritis | 1.09 (1.04, 1.14) | 0.91 (0.86, 0.96) |
| Osteoarthritis | 1.08 (1.05, 1.10) | 1.15 (1.12, 1.17) |
| Gastrointestinal risk level | ||
| Low | 1 (reference) | 1 (reference) |
| Moderate | 1.29 (1.25, 1.32) | 1.37 (1.34, 1.40 |
| High | 1.31 (1.27, 1.35) | 1.43 (1.39, 1.47) |
| Very high | 1.30 (1.19, 1.43) | 1.34 (1.21, 1.49) |
| Cardiovascular risk level | ||
| Low | 1 (reference) | 1 (reference) |
| Moderate | 0.92 (0.90, 0.95) | 0.89 (0.88, 0.91) |
| High | 0.81 (0.79, 0.84) | 0.86 (0.84, 0.89) |
| Very high | 0.59 (0.56, 0.62) | 0.73 (0.70, 0.77) |
| Congestive heart failure risk level | ||
| Low | 1 (reference) | 1 (reference) |
| Moderate | 0.98 (0.95, 1.00) | 1.00 (0.98, 1.03) |
| High | 1.10 (1.07, 1.13) | 1.18 (1.15, 1.22) |
| Very high | 1.02 (0.95, 1.08) | 1.06 (0.99, 1.14) |
| Renal risk level | ||
| Low | 1 (reference) | 1 (reference) |
| Moderate | 1.04 (1.01, 1.06) | 1.03 (1.01, 1.05) |
| High | 0.99 (0.92, 1.07) | 0.90 (0.84, 0.96) |
| Very high | 1.06 (0.99, 1.13) | 1.05 (0.98, 1.12) |